Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Roku Inc. Class A Common Stock (ROKU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Roku Inc. Class A Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Roku Inc. Class A Common Stock trades at $152.43 (market cap $22.67B). The key difference: Roku Inc. Class A Common Stock is far larger — about 2.6× Kymera Therapeutics Inc. Common Stock's market cap, and Roku Inc. Class A Common Stock is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Roku Inc. Class A Common Stock for 6 Days on average.
| KYMR | ROKU | |
|---|---|---|
Market Cap | $8.87B | $22.67B |
Volume | 779,107 | 1,039,228 |
Sector | Health | Media |
52-Week High | $127.31 | $159.76 |
52-Week Low | $55.80 | $82.93 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.26B | $20.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roku trades at $152.66, down slightly by 0.1% today. The stock shows mixed technical signals with a neutral overall rating. Fundamentally, revenue growth is solid with 2026 projections at $5.2B, while profitability improved significantly with net income margin rising to 6.81%. Recent earnings beats and the pending Fox acquisition approval highlight positive momentum. Analyst consensus is evenly split between Buy and Hold with a $161.38 price target.
Outlook remains cautiously optimistic with strong earnings performance and acquisition synergies offering upside potential. Key risks include regulatory scrutiny of the Fox deal, competitive pressures in streaming, and negative cash flow trends. The stock presents a growth opportunity if execution continues, but investors should monitor acquisition progress and profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Roku Inc. Class A Common Stock
Roku operates a streaming platform that combines its operating system, streaming devices, TV partnerships, and advertising services. It connects viewers with streaming content and services.
Read more on ROKU →
